Lilly cleared two additional trials for its triple-action obesity candidate retatrutide and will seek FDA approval in Q1 2027, advancing competition in the high

Trump administration announces a two-year tariff freeze on generic drug imports, followed by escalating duties reaching 100% by 2028, aimed at pushing domestic

Novo Nordisk files false advertising lawsuit against Lilly alleging misleading promotion of obesity drugs Zepbound and Mounjaro, escalating competitive tensions

Roche reports first-half revenue decline driven by currency effects while core drugs including Vabysmo maintain positive trajectories, reaffirming full-year gui

NovoCure reports strong Q2 results with Optune Pax, its next-generation tumor-treating fields device, accelerating recovery in the company's core oncology franc

An FDA advisory committee votes to permit compounding of the popular peptide BPC-157, overriding the agency's earlier position on the unapproved therapeutic.

Prime Medicine receives FDA approval for its investigational new drug targeting H1069Q-mutated Wilson disease and plans to initiate human studies in the second

BridgeBio gains FDA acceptance for encaleret as a potential first therapy specifically approved for autosomal dominant hypocalcemia-1, with decision expected by

Novartis reports stronger-than-expected results and announces FDA approvals and strategic acquisitions that strengthen oncology and specialty care portfolios.

GlaxoSmithKline receives early FDA approval for its first-in-class ROS1-targeted lung cancer therapy Jideytro, expanding treatment options for the rare mutation

Kolon TissueGene stock collapses following disclosure that its lead regenerative medicine candidate failed to meet efficacy endpoints in late-stage knee osteoar

Arrowhead stock jumps on analyst upgrades citing positive data for its RNA interference pipeline and portfolio momentum in rare genetic diseases.

West Pharmaceutical Services boosts earnings outlook citing robust order growth in vials, syringes, and prefilled injection systems driven by obesity drug expan

Celcuity gains FDA clearance for its molecular breast cancer test to identify patients likely to benefit from hormone-targeted therapy, expanding precision onco

Pfizer reports favorable late-stage data for its PARP inhibitor TALZENNA in combination therapy, supporting continued development in multiple cancer indications

Servier completes multi-billion dollar acquisition of Day One Biopharmaceuticals, strengthening development of pediatric and rare cancer programs.

Roche-owned Genentech narrows its obesity program focus following its acquisition of a regional biotech, consolidating efforts on most promising candidates.

Summit Therapeutics releases additional efficacy data for its checkpoint inhibitor ivonescimab as regulatory decision approaches, positioning the asset for pote